# OnCo record capitello-281 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/capitello-281/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "capitello-281", "NCT04493853" ;
  schema:name "CAPItello-281"@en ;
  schema:description "CAPItello-281 delivered the first AKT inhibitor success in prostate cancer, for the ~25% of men whose tumours have lost PTEN on the trial's own immunohistochemistry cut-off."@en ;
  schema:url <https://onco.cc/trials/capitello-281/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04493853> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2020-07-13" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mhspc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/> ;
  onco:targets <https://onco.cc/targets/akt/> ;
  onco:drugs <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/drugs/abiraterone/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-capitello-281-ann-oncol-2026/> .